Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main
protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related …

Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …

Nirmatrelvir plus ritonavir (Paxlovid™; Pfizer) is a co-packaged combination of nirmatrelvir
and ritonavir tablets, intended for co-administration and developed for the treatment and …

Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF …

The rapid development of effective vaccines to combat the SARS-CoV-2 virus has been an
effective counter measure to decrease hospitalization and the mortality rate in many …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …